title: Lack of association between serum paraoxonase 1 activities and increased oxidized low-density lipoprotein levels in impaired glucose tolerance and newly diagnosed diabetes mellitus.
abstract: Several in vitro investigations showed that serum paraoxonase 1 (PON1) that is located on high-density lipoprotein reduces or prevents low-density lipoprotein (LDL) oxidation and therefore retards atherosclerosis. Accordingly, the well documented loss of PON1 activity in patients with overt diabetes mellitus was causally related to the development of micro- and macroangiopathy in the disease course. Because vascular complications start already in prediabetic states, e.g. impaired glucose tolerance (IGT), we investigated serum PON1 activities and circulating levels of oxidized LDL (oxLDL) in 125 IGT subjects, 75 patients with newly diagnosed diabetes mellitus type 2, and 403 individuals with normal glucose tolerance. Using three different substrates (paraoxon, phenylacetate, p-nitrophenylacetate) we found that PON1 activity is not significantly altered in IGT and diabetes mellitus subjects, respectively, when compared with normoglycemic controls. Both IGT subjects and diabetes mellitus patients had significantly increased levels of oxLDL in the circulation. However, serum PON1 activity variations and glutamine/arginine phenotype were not related to the levels of oxLDL. The data suggest that 1) PON1 activity loss is an event occurring later in the course of diabetes mellitus; and 2) PON1 does not affect oxidation of circulating LDL, at least in early diabetes mellitus.
authors.affiliation: Department of Internal Medicine 3, Carl Gustav Carus Medical School, University of Technology Dresden, Germany. Steffi.Kopprasch@mailbox.tu-dresden.de
authors.forename: Steffi
authors.initials: S
authors.lastname: Kopprasch
authors.forename: Jens
authors.initials: J
authors.lastname: Pietzsch
authors.forename: Eberhard
authors.initials: E
authors.lastname: Kuhlisch
authors.forename: Juergen
authors.initials: J
authors.lastname: Graessler
mesh_terms: D000328:Adult; D000368:Aged; D043303:Aryldialkylphosphatase; D002096:C-Peptide / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000097:blood*; D004950:Esterases / Q000097:blood*; D005260:Female; D018149:Glucose Intolerance / Q000097:blood*; D006442:Glycated Hemoglobin / Q000032:analysis; D006706:Homeostasis; D006801:Humans; D007328:Insulin / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood*; D008297:Male; D008875:Middle Aged; D010261:Paraoxon / Q000378:metabolism; D010641:Phenotype; D010648:Phenylacetates / Q000378:metabolism; D013379:Substrate Specificity
chemical_list: D043303:Aryldialkylphosphatase; D002096:C-Peptide; D004950:Esterases; D006442:Glycated Hemoglobin; D007328:Insulin; D008077:Lipoproteins, LDL; D010261:Paraoxon; D010648:Phenylacetates; C099252:oxidized low density lipoprotein; C468406:PON1 protein, human; C025136:phenylacetic acid; C118008:4-nitrophenylacetic acid